A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common ...

Regeneron (REGN) stock is in focus as the firm fails in a late-stage trial testing a combination therapy involving its ...

The FDA has approved an oral combination therapy for certain adults with newly diagnosed acute myeloid leukemia.Decitabine ...

Adults with moderate to severe psoriasis and overweight or obesity were more likely to achieve complete skin clearance plus ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be ...

FDA cleared oral decitabine/cedazuridine plus venetoclax for frontline AML in adults ≥75 years or with comorbidities that make intensive induction inappropriate. Study ASTX727-07 (single-arm, ...

The Scottish Medicines Consortium has approved a new first-line combination therapy for restricted use in adults with unresectable or metastatic urothelial cancer.

Cancer immunotherapy is built on a simple but powerful idea: the immune system can recognize and destroy cancer cells if it ...

High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively ...

Should pharmacologic treatment of type 2 diabetes start with combination therapy or metformin monotherapy, adding other agents over time? This question was debated at the recent American Diabetes ...

Dr Bertram Pitt explains the possibility of combining SGLT2 inhibitors and MRAs when treating CKD and CV, and Paul Sapia, MHA, discusses how payers balance cost of care with disease progression and ...